Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + 7+3 in Poor-Risk AML
NCT02403310Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Primary endpoint: Maximal Tolerated Dose up to 18 months. Started Jun 2015; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02403310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403310.